{"contentid": 488202, "importid": NaN, "name": "Roche\u00e2\u0080\u0099s Evrysdi approved in Europe to ramp up SMA rivalry", "introduction": "Swiss pharma giant Roche has seen its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) follow up its US approval by getting the green light from the European Commission (EC).", "content": "<p>Swiss pharma giant Roche (ROG: SIX) has seen its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) follow up its US approval by getting the green light from the European Commission (EC).</p>\n<p>Evrysdi has been approved in the European Union (EU) for the treatment of 5q SMA in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.</p>\n<p><span class=\"pullQuote\">\"The first and only SMA treatment with proven efficacy that can be taken at home\"</span>SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease. The condition causes muscle weakness and progressive loss of movement and significant unmet need remains, particularly in adults living with this condition.</p>\n<p>Levi Garraway, Roche&rsquo;s chief medical officer and head of global product development, said: &ldquo;Today&rsquo;s approval of Evrysdi, the first and only SMA treatment with proven efficacy that can be taken at home, potentially transforms treatment options for a broad range of people with SMA living in the EU.</p>\n<p>&ldquo;By avoiding the need for in-hospital administration, Evrysdi can reduce the treatment burden on those living with SMA, their caregivers and healthcare systems.&rdquo;</p>\n<p>Roche&nbsp;is working closely with reimbursement and assessment bodies in European countries to enable broad and rapid access to patients in need. Evrysdi will be accessible to patients in Germany in the coming days and in France from early April through the cohort Temporary Authorization for Use.</p>\n<p>Reimbursement dossiers have been submitted in many countries in anticipation of the decision by the EC to minimize any delay in patient access.</p>\n<p>Roche&nbsp;leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics (Nasdaq: PTCT).</p>\n<p>The drug is part of a competitive SMA market where existing treatments are Biogen&rsquo;s (Nasdaq: BIIB) Spinraza (nusinersen) and Novartis&rsquo; (NOVN: V) Zolgensma (onasemnogene abeparvovec).</p>\n<p>&nbsp;</p>", "date": "2021-03-30 13:46:00", "meta_title": NaN, "meta_keywords": "Evrysdi, treatment, European, approval, drug, approved, Roche\u00e2\u0080\u0099s, Type, ramp, Europe, rivalry, giant, spinal, muscular, atrophy, pharma, risdiplam, follow", "meta_description": "Swiss pharma giant Roche has seen its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) follow up its US approval by getting the green light from the Europ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 13:34:33", "updated": "2021-03-30 14:20:10", "access": NaN, "url": "https://www.thepharmaletter.com/article/roche-s-evrysdi-approved-in-europe-to-ramp-up-sma-rivalry", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_roche_big.jpg", "image2id": "2020_roche_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Musculoskeletal, Rare diseases", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe, Switzerland", "company_tag": "PTC Therapeutics, Roche, SMA Foundation", "drug_tag": "Evrysdi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 13:46:00"}